CNTA
Centessa PharmaceuticalsCNTA
CNTA
About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
Employees: 98
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
439% more call options, than puts
Call options by funds: $6.01M | Put options by funds: $1.12M
29% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 34
1.28% less ownership
Funds ownership: 93.79% [Q1] → 92.51% (-1.28%) [Q2]
10% less capital invested
Capital invested by funds: $1.8B [Q1] → $1.62B (-$174M) [Q2]
10% less funds holding
Funds holding: 129 [Q1] → 116 (-13) [Q2]
29% less funds holding in top 10
Funds holding in top 10: 14 [Q1] → 10 (-4) [Q2]
37% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 30
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
76%
upside
Avg. target
$32
86%
upside
High target
$35
106%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Rudy Li | 76%upside $30 | Buy Maintained | 12 Aug 2025 |
Truist Securities Danielle Brill | 76%upside $30 | Buy Initiated | 21 Jul 2025 |
Needham Ami Fadia | 106%upside $35 | Buy Initiated | 28 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
Neutral
GlobeNewsWire
1 month ago
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).
Positive
Zacks Investment Research
2 months ago
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
Centessa Pharmaceuticals (CNTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders. ORX142 is the second drug candidate from the Company's multi-asset orexin franchise.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
The consensus price target hints at a 138.8% upside potential for Centessa Pharmaceuticals (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
3 months ago
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Neutral
GlobeNewsWire
3 months ago
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
BOSTON and LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
5 months ago
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2024.
Neutral
GlobeNewsWire
5 months ago
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.
Neutral
GlobeNewsWire
7 months ago
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.
Charts implemented using Lightweight Charts™